Incyte Pharmaceuticals, Inc.

Incyte Corporation

Incyte Genomics, Inc.

Other

Eli Lilly and Company

University of Toronto

California Biotechnology Inc.

Biotechnology Research Partners, Ltd.

Jeffrey J Seilhamer

Phillip R Hawkins

Janice K Au-Young

Roger T Coleman

Craig G Wilde

Karl J Guegler

Susan G Stuart

Benjamin Graeme Cocks

Olga Bandman

Lynn E Murry

Scott Michael Braxton

Ingrid E Akerblom

Scott R Panzer

Gary B Zweiger

Mary Jane Cunningham

Richard D Goold

Jennifer L Hillman

Lorin K Johnson

Randal W Scott

Tod M Klingler

Timothy J Maslyn

Glenn E Nedwin

Jay A Tischfield

Peter Vadas

Tim Bringman

Douglas A Fisher

Waldemar Pruzanski

Christina M Altus

Preeti G Lal

Purvi Shah

Surya K Goli

Robert M Scarborough

Y Tom Tang

Henry Yue

Mariah R Baughn

John A Lewicki

Frank D Russo

Matthew R Kaser

Dinh Diep

Yalda Azimzai

Angelo M Delegeane

J Gordon Porter

Thomas J Dull

Pierre-Olivier Couraud

Rachel J Cheng

Pierre-Oliver Couraud

Steven M Lassagne

Srikar D Rao

Steve E Lincoln

Wendy B Levine

Samuel T LaBrie

Timothy M Engler

James R Kerr

The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.

Methods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid

Methods of treatment with anitbodies to a chemokine expressed in inflamed adenoid

The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Antibodies to a cathepsin C homolog

The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.

Human myeloid terminal differentiation response gene

Antibodies to a chemokine expressed in inflamed adenoid

The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes for the composition.

Compositions for the detection of blood cell and immunological response gene expression

The present invention provides nucleotide and amino acid sequences that identify and encode novel cellubrevins (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cbs, expression vectors for the production of purified CBs, antibodies capable of binding specifically to CBs, hybridization probes or oligonucleotides for the detecting the induction of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CBs, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CBs.

Cellubrevin homologs

The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes of the composition.

Composition for the detection of signaling pathway gene expression

A biomolecular expression information processing system has procedures and tables that store abundance datasets and hybridization data. The tables also store information identifying a microarray technology type for each hybridization and microarray design information for each microarray technology type. The microarray design information includes technology data that specifies global characteristics of each microarray, and array element data that specifies characteristics of array elements in each microarray instance of the microarray technology type. The procedures process the abundance datasets in accordance with the microarray design information associated with each such abundance dataset. The system stores technology data for multiple distinct microarray technology types and stores array element data for multiple microarray designs of a single technology type.

System and method for generating, analyzing and storing normalized expression datasets from raw expression datasets derived from microarray includes nucleic acid probe sequences

Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds &bgr;-galactoside-containing moieties independent of the presence or absence of Ca , stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.

Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells

The present invention relates to a composition comprising a plurality of polynucleotide targets. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to methods for screening compounds and therapeutic treatments for toxicological responses.

Toxicological response markers

The present invention relates to mammalian nucleic acid and protein molecules comprising a plurality of nucleic acid and protein molecules. The mammalian nucleic acid molecules can be used as hybridizable array elements in a microarray in diagnostic and therapeutic applications including detecting metabolic and toxicological responses, and in monitoring drug mechanism of action. The protein molecules can be used in a pharmaceutical composition. The present invention also relates to methods for screening compounds and therapeutics for metabolic responses indicative of a toxic compound or molecule.

Mammalian toxicological response markers

Novel mammalian phospholipase (PLA ) nucleotide sequences and low molecular weight (about 14 KD) amino acid sequences encoded thereby are disclosed. More particularly, a cloned human HPLA cDNA expressing HPLA -10 and its cloned rat RPLA cDNA counterpart, expressing RPLA -10, which are characterized as PLA Type IV, are disclosed. A second type of PLA cDNA, characterized as PLA Type III and exemplified by a rat PLA cDNA encoding RPLA -8 and a partial human PLA nucleotide sequence encoding HPLA -8, is disclosed. Expression of the cDNAs encode the two new types of PLA enzymes which have phospholipase activity. The novel PLA s do not include disulfide bridges between cysteine amino acids 11 and 77 or elapid loops. However, the novel PLA s may include amino acid COOH-terminal extensions which can vary in length. Seventeen of the eighteen absolutely conserved amino acids in all active 14 KD PLA s are believed to be conserved in RPLA -8 and HPLA -8, whereas all eighteen are believed to be conserved in RPLA -10 and HPLA -10. Because the encoded sequences of RPLA -8 and HPLA -8 include only 16 cysteine amino acids, they have been designated as Type III. RPLA -10 and HPLA -10 are designated as Type IV since their encoded sequences include only 12 cysteine amino acids.

Mammalian phospholipase A2 nucleotide sequences, low molecular weight amino acid sequences encoded thereby, antisense sequences and nucleotide sequences having internal ribosome binding sites

The present invention is a computerized storage and retrieval system for genetic information and related annotated information. The data of the system is stored in a relational database which interfaces with public databases to allow analysis both within the database of the invention and between information within that database and external public databases. The sequence data is edited before entry into the system, and is stored in a curated, functional clustering organization. The information associated with the data is stored in an expression database that is linked to the storage of the sequence data.

Database for storage and analysis of full-length sequences

Markers for peroxisomal proliferators

Growing community of inventors

Los Altos Hills, CA, United States of America

Jeffrey J Seilhamer